drugset / Trial / NCT06783569
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.
Timeline
- Start
- 2024-12-31
- Primary completion
- 2026-05
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JR8603 | Unknown | 1.7 mg/m2 | Intravenous |
| Subject | JR8603 | Unknown | 3.3 mg/m2 | Intravenous |
| Subject | JR8603 | Unknown | 7 mg/m2 | Intravenous |
| Subject | JR8603 | Unknown | 14 mg/m2 | Intravenous |
| Subject | JR8603 | Unknown | 21 mg/m2 | Intravenous |
| Subject | JR8603 | Unknown | 28 mg/m2 | Intravenous |
| Subject | JR8603 | Unknown | 35 mg/m2 | Intravenous |